Moleculin Biotech (Nasdaq: $MBRX): Annamycin, MIRACLE AML and the ASCO 2026 Cardiac Safety Update

01 MIRACLE shows a numerical advantage over control, but the July 31 financing rewrites the risk/reward profile

The first randomized 45-patient unblinding showed CR of 43% and 36% in the two Annamycin arms versus 12% for control. Enrollment has reached 74 of 90 patients and the comprehensive Part A readout is expected between December 2026 and February 2027. At the same time, Moleculin launched a best-efforts public offering for up to 11.09 million common shares and 1.29 million pre-funded warrants, together with up to 37.13 million common warrants at a combined $0.75 price. If fully sold, the prospectus estimates approximately $8.5 million of net proceeds. The offering can remain open through August 14 unless terminated earlier, so the maximum proceeds and final post-offering share count were not yet confirmed at this cut-off.

A complete analysis of Annamycin after the favorable preliminary 45-patient unblinding, the new signal in post-venetoclax patients, progress toward 90 subjects and the warrant-heavy public offering that transformed the capital structure.

02 Executive Summary: The Science Moved Forward, the Equity Story Moved Backward

Moleculin Biotech is a clinical-stage oncology biotech whose near- and medium-term value depends overwhelmingly on Annamycin, or naxtarubicin, a next-generation liposomal anthracycline developed to bypass multidrug resistance and reduce the cardiotoxicity associated with the class. The central program is MIRACLE, a pivotal adaptive Phase 2/3 trial comparing two doses of Annamycin plus high-dose cytarabine with cytarabine plus placebo as second-line therapy in relapsed or refractory acute myeloid leukemia.

On June 30, 2026, the company reported its first true clinical inflection point. In the full intent-to-treat analysis of the first 45 patients, with no exclusions, both doses numerically outperformed control on the primary endpoint of complete remission. The 190 mg/m² arm achieved 43% CR, the 230 mg/m² arm achieved 36% CR and control achieved 12% CR. CRc was 50%, 57% and 29%, respectively. The dataset did not achieve statistical significance, as expected under a highly conservative early O’Brien-Fleming boundary, but the Independent Data Monitoring Committee identified a strong favorable trend and recommended that both doses continue.

On July 31, Moleculin then reported 62 evaluable patients, 74 enrolled out of 90 and a 37% blinded CRc rate both in the overall population and among the 30 patients who had previously failed venetoclax. That is encouraging because the trial mix became harder without a collapse in remission rates. The analysis, however, remains blinded, includes control, is descriptive and is not powered for subgroup comparisons.

On the same day, the company priced an approximately $9.3 million gross public offering at $0.75, consisting of 12.38 million shares or pre-funded warrants plus 37.13 million warrants carrying a $0.75 strike and a five-year term from the applicable initial exercise date, subject to the conditions and any approvals described in the offering documents. The financing reduces immediate cash risk and should help advance MIRACLE toward the complete Part A readout, but the amount of potential paper is enormous relative to the 7.1 million shares outstanding disclosed as of June 30.

The clean reading: clinical risk declined after the 45-patient unblinding; per-share risk increased after the offering. The next step is no longer proving that a signal exists, but confirming dose, robustness, full safety and financial sustainability in the 90-patient dataset.

03 The Three News Events That Completely Changed the Hub

04 The First MIRACLE Unblinding: Randomized Clinical Numbers at Last

The June 30 analysis included 45 patients in the full intent-to-treat population: 14 in the Annamycin 190 mg/m² plus HiDAC arm, 14 in the 230 mg/m² plus HiDAC arm and 17 in the HiDAC-plus-placebo control. After one cycle, the 190 mg/m² arm reported 43% CR and 50% CRc; the 230 mg/m² arm reported 36% CR and 57% CRc; control reported 12% CR and 29% CRc.

The absolute CR advantage was therefore 31 percentage points for the 190 dose and 24 points for the 230 dose. For CRc, the advantage was 21 and 28 points. The most important feature is not the comparison with historical benchmarks, but the presence of a concurrent control treated under the same protocol, during the same period and after the same single cycle.

The lower dose produced the nominally higher CR rate, while the higher dose produced the higher CRc rate. That helps explain why the iDMC did not recommend dropping an arm: with only 14 patients per dose, the differences are too small and noisy to select the optimal dose reliably. Dose selection requires the complete efficacy, safety, pharmacokinetic and response-quality package at 90 patients.

05 Why “Positive” Does Not Yet Mean “Confirmed”

The iDMC unanimously concluded that there was a strong numerical trend favoring the experimental arms and sufficient evidence to continue. It did not declare statistically significant efficacy. That distinction is not cosmetic. MIRACLE uses an O’Brien-Fleming spending function that sets a very high threshold at early interim analyses and preserves nearly all alpha for the final analysis, designed for approximately 282 patients and 80% power to distinguish, under the protocol assumption, 20% CR in control from 35% CR in treatment.

An n=45 dataset is enough to test direction and plausibility, but not to close the registration debate. Investors still need remission duration, early mortality, infections, non-cardiac toxicity, subsequent transplant, response quality, molecular-risk distribution, performance after venetoclax and consistency between doses.

The statistical point: the lack of significance at the first interim is not a failure because significance was not required to continue. It cannot be turned into definitive proof either. The value of the readout depends on confirmation in the complete Part A dataset and then in the pivotal portion.

06 The July 31 Post-Venetoclax Update: Encouraging, but Still Blinded

At the July 18 data cut, 62 patients were evaluable. Preliminary blinded CR was 24% and CRc was 37%. Thirty patients, or 48% of the evaluable population, had failed a first-line venetoclax-based regimen; within that subgroup CR was 23% and CRc was 37%, essentially identical to the overall population.

The stability of the signal is notable because the post-venetoclax share increased from 31.1% in the n=45 population to 48% in the n=62 dataset. In other words, the study absorbed a harder patient mix without blinded CRc falling outside the approximately 37-40% range seen across sequential analyses.

The company compares this with a published retrospective cohort in which only 13% of patients receiving salvage therapy after venetoclax plus a hypomethylating agent achieved CR/CRi and median overall survival was 2.4 months. The comparison is useful context, but not controlled: the historical cohort was small, single-center, heterogeneous and different from the MIRACLE protocol.

Prudent interpretation: the post-venetoclax data strengthen the plausibility that Annamycin retains activity in a difficult population. They do not yet show how much of the remission activity belongs to Annamycin because the 62-patient analysis remains blinded and includes control.

07 Enrollment and the New Timeline: The Next Real Reset Straddles 2026 and 2027

The calendar has therefore been reset. The market should not expect a second major unblinding immediately after the summer. Completion of Part A requires treatment, evaluation, data cleaning, audit, database lock and a broader endpoint package needed for dose selection and the transition to Part B.

The company expects to treat the 90th patient in September and report comprehensive results between December 2026 and February 2027. That creates a multi-month period in which the stock will be driven by enrollment, financing, possible safety updates, regulatory work and sentiment rather than a new randomized readout.

08 MIRACLE Trial Design: Why Part A Is More Than Ordinary Dose-Finding

MIRACLE is a global, multicenter, randomized, double-blind, placebo-controlled adaptive study. Part A compares Annamycin 190 mg/m² plus HiDAC, Annamycin 230 mg/m² plus HiDAC and HiDAC plus placebo. Part B is expected to carry one optimal dose forward against control, with Part A data carried into the pivotal efficacy analysis.

This structure gives value to data already collected, but increases the importance of dose selection. A higher dose is not automatically better; it must offer the best balance of CR, CRc, safety, pharmacokinetics and treatment completion. Both arms beating control is positive. Neither clearly dominating the other makes the 90-patient dataset even more important.

The trial enrolls adults in second line after one prior induction therapy. As of July 31, the company reported patients from seven countries and 33 sites that had undergone site-initiation visits, with a target of at least 45 sites for Part B. European recruitment has contributed more than U.S. recruitment, which Moleculin said it intends to improve.

09 Annamycin and Cardiac Safety: Real Differentiation, but Not a Complete Answer

Anthracyclines are powerful but limited by cumulative cardiotoxicity. Annamycin was designed with a multilamellar lipid delivery system to improve distribution, bypass multidrug resistance and reduce cardiac injury. The ASCO 2026 poster reported no detectable cardiotoxicity in pooled completed-study data, supported by independent cardiac review, ejection-fraction assessments, ECGs, biomarkers and other available measures.

On July 31, the company reiterated that no evidence of cardiotoxicity had emerged in MIRACLE based on reported ejection fractions and adverse events. That matters because Annamycin’s clinical value is not simply producing remissions, but doing so with a historically effective drug class without its defining safety limitation.

The correct wording remains “no signal observed to date,” not “cardiac risk eliminated.” The dataset is still limited, follow-up continues and registration will require a complete safety assessment, not cardiac safety alone.

10 The July 31 Financing: Operational Oxygen in Exchange for a Radically Heavier Cap Table

Moleculin priced a best-efforts offering of 12,376,667 common shares, or pre-funded warrants in lieu thereof, accompanied by warrants to purchase up to 37,130,001 shares. The combined price is $0.75 per share or PFW with associated warrants. The warrants carry a $0.75 strike and are structured to become exercisable from the applicable initial exercise date under the offering documents, subject to closing and any stockholder approval required by Nasdaq rules; they expire five years after that initial exercise date. Closing is expected on or about August 3, 2026, subject to customary conditions.

Gross proceeds are approximately $9.3 million; net proceeds will be lower after commissions and expenses. The Form 10-Q cover confirms what that did to the count: 19,477,380 shares outstanding at August 6, 2026, against the 7.10 million that market-data providers were still showing two weeks later. Any market capitalisation built on the old number understates the company by nearly three times. The company intends to use the capital to advance Annamycin and for working capital. In the preliminary registration statement, Moleculin said completion of the maximum offering could fund current-plan capital needs into the first quarter of 2027. That is better than the prior Q3 2026 runway, but still short relative to a complete pivotal program.

The issue is not only the new shares. Each unit includes three warrants, creating 37.13 million additional potential shares. Full cash exercise at $0.75 could generate approximately $27.85 million in gross proceeds, but only if the market price is sufficiently above the strike and exercise is not guaranteed. Until then, the warrants create a very large overhang.

Key message: the raise reduces the risk that MIRACLE stops for lack of cash in the immediate term. It does not remove long-term financing risk and transfers substantial risk to shareholders through immediate dilution, warrants and possible repricing of existing instruments.

11 Capital Stack: How Large Is the Potential Dilution?

The S-1/A reports 7.1 million shares outstanding as of June 30, 2026. Relative to that base, the 12.38 million shares or PFWs increase common-equivalent shares by approximately 174%, taking the illustrative post-offering basic-equivalent to approximately 19.48 million after closing and any PFW exercise. Under that illustration, pre-offering holders fall from 100% to approximately 36.5% of post-offering basic-equivalent ownership.

The offering also adds 37.13 million new warrants, while the filing reported 12.44 million pre-existing warrants. Adding only these categories, without options, RSUs or further adjustments, produces an illustrative fully diluted total of approximately 69.05 million shares. That is not current shares outstanding and does not imply all warrants will be exercised; it shows the scale of overhang relative to the pre-offering base.

Illustrative capital stack after the offering

Millions of shares or potential shares. Assumes full exercise; does not represent current shares outstanding.

The illustrative total of the four categories is approximately 69.05M. It excludes options, RSUs, possible amendments and beneficial-ownership limitations.

The filing also warns that Series G and Series H warrants, together covering 8,978,779 potential shares, contain anti-dilution protection. A sale below their exercise price may reduce the strike to floor prices of $1.326 and $0.962, respectively. Because the offering was priced at $0.75, repricing toward those floors is a concrete risk and brings a large portion of the pre-existing overhang closer to market.

12 Updated Financial Snapshot: Cash Improves, Burn Does Not Disappear

The latest filed quarterly balance sheet remains March 31, 2026, when Moleculin reported approximately $10.3 million in cash and cash equivalents. Q1 R&D expense was approximately $5.4 million, G&A was approximately $2.5 million and net loss was approximately $12.8 million. Net loss includes accounting items and is not identical to cash burn, but it confirms the scale of capital needs for a nano-cap with no product revenue.

Second-quarter and July operating expenses must be deducted from that balance, so simply adding $9.3 million to the March cash figure would be incorrect. The more useful data point is the registration-statement guidance: with a maximum raise, the company believed it could fund its current plan into Q1 2027. That still does not cover development through registration.

13 Market Reaction and Retail Sentiment: Clinical Enthusiasm, Financing Distrust

The July 31 market reaction was violently negative after the offering price was announced. That does not necessarily contradict the clinical value of the data; it reflects the difference between program value and per-share value. An asset can improve while a stock falls if the market believes new shares and warrants absorb too much of the upside.

The August 1 Stocktwits snapshot showed “extremely high” message volume and tagged sentiment still “extremely bullish” despite the daily collapse. Discussion centered on three themes: potential technical bounces after the sell-off, anger over the timing of the financing and debate about the company’s ability to complete the 90-patient study. It is a useful example of retail sentiment that should not be confused with fundamental validation.

Sentiment note: Reddit, Stocktwits and X reflect comments from non-professional traders, often focused on the very short term. Sentiment can help measure crowding and volatility; it does not evaluate clinical efficacy or intrinsic value.

14 Company Overview and Pipeline Beyond MIRACLE

Moleculin is headquartered in Houston and develops an oncology and antiviral pipeline. Annamycin dominates valuation because it is the most advanced asset and the only one in an active pivotal trial. Beyond AML, the drug has been studied in soft tissue sarcoma lung metastases, and the company has discussed a possible externally supported third-line pancreatic cancer study.

WP1066 is an immune/transcription modulator associated with p-STAT3 and other oncogenic transcription factors, with programs in brain tumors, pancreatic cancer and other malignancies. WP1122 belongs to the antimetabolite and metabolism/glycolysis-inhibition portfolio, with possible oncology and antiviral applications. These programs create optionality, but they do not offset a MIRACLE failure in the near term.

15 AML Competitive Landscape: The Advantage Must Be Clinically Usable

R/R AML is fragmented by mutations, age, fitness, prior treatment and transplant eligibility. Targeted therapies exist for FLT3, IDH1, IDH2 and menin-related subgroups, alongside venetoclax combinations, hypomethylating agents, cytarabine-based regimens and experimental immune strategies. Annamycin does not need to prove there are no alternatives; it must demonstrate a credible advantage in a broad biomarker-agnostic population.

The potential positioning is an agent capable of producing deep remissions after one cycle, retaining activity after venetoclax failure, serving as a bridge to transplant and reducing the cardiac limitation of conventional anthracyclines. A strong clinical proposition also requires response duration, survival, complete safety, multicenter feasibility and a regulatory path aligned across the FDA and EMA.

16 Management, Governance and Ownership

Walter V. Klemp is co-founder, Chairman, CEO and President. His background includes co-founding Soliton, listing it on Nasdaq and later selling it to AbbVie, as well as other company-building experience in devices and healthcare. For Moleculin, however, the central test is not only creating an interesting asset; it is financing and completing a pivotal oncology program without destroying per-share value.

In the S-1/A, management and the board beneficially owned approximately 406,579 shares or instruments exercisable within 60 days, representing 5.4% on a base of 7.1 million shares as of June 30. Walter Klemp was listed at 3.9%, including a substantial option and warrant component. The filing listed no holders above 5%.

Those percentages will decline after the new offering. Insider alignment should therefore be monitored through open-market purchases, participation in the offering, equity compensation and future financing decisions.

17 Analysts and the Valuation Framework After the Offering

Any price target published before July 31 must be rebuilt around the new capital structure. In a nano-cap with reverse splits, warrant inducements, new shares and anti-dilution instruments, a nominal target is not useful without fully diluted share count, capital required through registration and a risk-adjusted probability of success.

The more useful framework is a sequence of questions: which dose will be selected? Will the CR advantage remain close to the first interim? Will control stay near 12% or rise? Will the post-venetoclax CRc signal be confirmed unblinded? How much cash is needed for Part B? How many warrants become economically exercisable? Is a partner willing to fund the program?

18 Updated Catalyst Map

19 Bull, Base and Bear Scenarios After Data and Financing

20 Red Flags That Cannot Be Ignored

• Sample size: the first unblinding contains only 14 patients per dose and 17 in control.
• No statistical significance: consistent with the interim design, but the advantage must be confirmed.
• Early endpoint: remission after one cycle does not replace duration, survival and full clinical quality.
• Dilution: new shares/PFWs exceed the pre-offering share base; new warrants are more than five times that base.
• Warrant repricing: existing instruments can move closer to market through anti-dilution floors.
• Runway remains limited: even after the offering, Moleculin expects additional funding needs before registration.
• Nasdaq compliance: the company had bid-price and equity issues in 2025; volatility remains a risk.
• Execution: Part B requires sites, capital, dose selection, regulatory work and required nonclinical completion.

21 Updated Timeline

22 Merlintrader Bottom Line

Moleculin has finally produced the missing dataset: Annamycin did not merely beat historical benchmarks in a pooled blinded analysis; it numerically outperformed a concurrent randomized control on CR and CRc. That materially reduces the risk that the program was supported only by favorable historical comparisons.

The data remain preliminary, small and not statistically significant. The market still needs the complete 90-patient package, dose selection, remission duration, full safety and the company’s ability to move into Part B. The post-venetoclax signal is interesting, but it is not yet unblinded.

The new offering solves part of the near-term cash problem while creating a major capital-structure problem. MBRX therefore cannot be read simply as a “positive trial.” It is a story in which asset value can rise while per-share value remains under pressure. The next several months revolve around two questions: will MIRACLE confirm the advantage, and how much of that advantage will remain for shareholders after shares, warrants and future capital?

Track upcoming events on the Merlintrader Biotech Catalyst Calendar.

The block below is a snapshot of the Stocktwits flow, with its date. These are opinions of retail traders and non-professional investors, not analyst research, and they measure attention and how one-sided positioning has become rather than anything about the business.

23 Get Biotech Updates in Real Time

Catalysts, FDA decisions, trial readouts and breaking news from the Merlintrader community.

This content is for informational and educational purposes only and is not financial, medical or personalized advice, or a recommendation to buy, sell or hold any security. Moleculin Biotech is a highly speculative clinical-stage biotech company. Clinical trials, regulatory decisions, financings, warrants, dilution, liquidity and Nasdaq requirements can produce substantial losses. Scenario analysis represents Interpretation, not guaranteed facts. Always verify current SEC filings and official company disclosures.